| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 56.874 | 180.443 | 426.265 | 601.373 | 755.160 | 1.092.702 | 1.505.790 | 2.196.061 | 2.991.121 | 3.438.908 |
| Total Income - EUR | 57.055 | 181.118 | 426.483 | 601.445 | 755.209 | 1.092.926 | 1.505.915 | 2.198.804 | 2.992.359 | 3.441.961 |
| Total Expenses - EUR | 50.846 | 160.590 | 402.353 | 552.097 | 695.913 | 963.895 | 1.356.171 | 2.021.272 | 2.773.758 | 3.200.366 |
| Gross Profit/Loss - EUR | 6.209 | 20.528 | 24.131 | 49.348 | 59.296 | 129.031 | 149.744 | 177.532 | 218.602 | 241.595 |
| Net Profit/Loss - EUR | 4.507 | 17.243 | 19.915 | 43.333 | 51.742 | 117.156 | 130.793 | 153.643 | 192.316 | 213.031 |
| Employees | 0 | 0 | 1 | 1 | 3 | 3 | 5 | 6 | 7 | 8 |
Check the financial reports for the company - Priotech Medpharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 445 | 438 | 430 | 1.508 | 923 | 404 | 459 | 54 | 53 |
| Current Assets | 31.912 | 50.499 | 95.913 | 148.872 | 208.217 | 333.968 | 487.213 | 611.567 | 496.271 | 806.127 |
| Inventories | 10.210 | 22.808 | 58.828 | 92.741 | 87.214 | 114.477 | 188.078 | 342.385 | 292.441 | 344.444 |
| Receivables | 19.318 | 24.655 | 30.838 | 36.274 | 69.965 | 55.190 | 80.337 | 161.312 | 160.666 | 315.843 |
| Cash | 2.384 | 3.036 | 6.247 | 19.857 | 51.038 | 164.301 | 218.799 | 107.870 | 43.164 | 145.841 |
| Shareholders Funds | 6.215 | 17.288 | 36.910 | 79.565 | 129.767 | 244.462 | 369.834 | 153.692 | 345.541 | 555.549 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 25.698 | 33.657 | 59.441 | 69.736 | 79.958 | 90.429 | 117.784 | 458.335 | 150.783 | 250.632 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4690 - 4690" | |||||||||
| CAEN Financial Year |
4690
|
|||||||||
Comments - Priotech Medpharma Srl